#Biopharma #Biologics #Biosimilars #BioBetters #PharmaceuticalIndustry #DrugDevelopment #PatentStrategy #LifeSciences #HealthcareInnovation #PrecisionMedicine #Biotech #PharmaTrends #AIinHealthcare To view or add a comment, sign in Your weekly round-up of whats happening across the world of generics and biosimilars
The STEP-2 trial demonstrated that semaglutide 2.4 mg reduced HbA1c by 1.6 percentage points in adults with obesity and type 2 diabetes, alongside 9.6% body weight loss [4]
4 The burden of MASLD is projected to increase exponentially, with anticipated rises of 21% and 63% in cases of MASLD and MASH, respectively
Medical researchers have discovered that semaglutide may reverse the debilitating tissue damage caused by osteoarthritis, the world's most common form of arthritis
With transparent pricing, personalized treatment plans, and unlimited access to licensed medical professionals, MEDVi delivers more than just medication it delivers a clear path to sustainable weight loss
Youre not on anyones timeline but your own